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Background: Peripheral neuropathy (PN) due to paclitaxel is a common dose-limiting 
toxicity with no effective prevention or treatment. We hypothesize that continuous-flow 
limb hypothermia can reduce paclitaxel-induced PN.
Patients and methods: An internally controlled pilot trial was conducted to investi-
gate the neuroprotective effect of continuous-flow limb hypothermia in breast cancer 
patients receiving weekly paclitaxel. Patients underwent limb hypothermia of one limb 
for a duration of 3 h with every paclitaxel infusion, with the contralateral limb used as 
control. PN was primarily assessed using nerve conduction studies (NCSs) before the 
start of chemotherapy, and after 1, 3, and 6 months. Skin temperature and tolerability to 
hypothermia were monitored using validated scores.
results: Twenty patients underwent a total of 218 cycles of continuous-flow limb hypo-
thermia at a coolant temperature of 22°C. Continuous-flow limb hypothermia achieved 
mean skin temperature reduction of 1.5 ± 0.7°C and was well tolerated, with no pre-
mature termination of cooling due to intolerance. Grade 3 PN occurred in 2 patients 
(10%), grade 2 in 2 (10%), and grade 1 in 12 (60%). Significant correlation was observed 
between amount of skin cooling and motor nerve amplitude preservation at 6 months 
(p < 0.0005). Sensory velocity and amplitude in the cooled limbs were less preserved 
Abbreviations: AH, abductor hallucis; CIPN, chemotherapy-induced peripheral neuropathy; cMAP, compound muscle action 
potentials; CTS, composite tolerability score; EDB, extensor digitorum brevis; NCI-CTC, National Cancer Institute-Common 
Toxicity Criteria grading of neuropathy; NCSs, nerve conduction studies; PN, peripheral neuropathy; PPMC, Pearson’s Product 
Moment Coefficient; SAS, Shivering Assessment Scale; SNAP, sensory nerve action potential; STS, subjective tolerance scale; 
TNS, Total Neuropathy Score; VAS, visual analog pain scale.
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inTrODUcTiOn
Chemotherapy-induced peripheral neuropathy (CIPN) is a 
common dose-limiting toxicity of paclitaxel. At present, dose 
modification remains the most successful approach for the man-
agement of CIPN, and pharmacological treatment is limited to 
alleviating symptoms such as paresthesias, dysesthesia, and pain 
(1). To date, none of the potential neuroprotective agents tested 
in clinical trials have proven effective (2).
The mechanisms of neurotoxicity in paclitaxel-induced 
peripheral neuropathy (PN) have not been fully elucidated; 
however, disruption of microtubule dynamics has been identi-
fied. Taxanes binding to β-tubulin components of microtubule 
assemblies lead to microtubule stabilization, thereby causing 
a disruption of microtubule dynamics (3, 4). It has also been 
observed that paclitaxel administration produces abnormalities 
in axonal mitochondria (5). Additional targets of neurotoxicity 
include direct axonal toxicity at the distal nerve terminals (6). 
Patients with pre-existing conditions that are capable of inducing 
PN (such as diabetes, Charcot–Marie–Tooth, or kidney disease) 
are particularly predisposed to developing CIPN (7).
Given the dose-dependent pathophysiology of paclitaxel-
induced PN, we proposed a novel strategy for prevention of 
paclitaxel-induced PN by employing continuous-flow limb 
hypothermia to reduce delivery of the toxic chemotherapeutic 
agents to the peripheral nerves. Our previous in  vivo study 
showed that a drop in rat sciatic nerve temperature from 30 
to 20°C produced a fivefold reduction of nerve blood flow (8). 
Furthermore, in studies of chemotherapy-induced alopecia 
(CIA), which is a result of toxic accumulation of chemothera-
peutics in the hair follicle, there is compelling evidence that 
cooling of the scalp protects against the development of CIA 
(9, 10). The rationale behind using hypothermia in the preven-
tion of CIA is that scalp cooling decreases the blood supply to 
the hair follicles, and hence, hair follicle protection is a result 
of reduced delivery of toxic chemotherapeutics (10). However, 
scalp cooling employing traditional cooling methods such as 
ice packs is poorly tolerated, which limits efficacy of the treat-
ment itself (11). Hence, we employed a better-tolerated and 
efficient cooling technique of continuous-flow hypothermia. In 
a previous study in healthy subjects, we also established that 
continuous-flow limb hypothermia at a coolant temperature 
of 22°C was the lowest tolerable temperature for a duration 
of 3 h, matching the duration of paclitaxel infusion in cancer 
patients (12).
The goal of the current study was to determine if continuous-
flow limb hypothermia may be neuroprotective in patients 
receiving paclitaxel chemotherapy, as well as assessing safety and 
tolerability.
PaTienTs anD MeThODs
study Design
This prospective study was carried out in accordance with the 
recommendations of the Institutional Review Board of the 
National Health Group, Singapore, with written informed 
consent from all subjects. All the subjects gave written informed 
consent in accordance with the Declaration of Helsinki. The 
study population comprised breast cancer patients scheduled 
to receive adjuvant weekly paclitaxel chemotherapy for 12 
cycles following standard anthracycline-based chemotherapy 
(doxorubicin and cyclophosphamide). (For detailed inclusion/
exclusion criteria, see supplementary material.) During every 
cycle of chemotherapy, premedication drugs (dexamethasone, 
diphenhydramine, and ranitidine) were administered 30  min 
prior to paclitaxel infusion. 80 mg/m2 of paclitaxel was admin-
istered as a 1-h infusion (indicated in orange in Figure 1A). The 
chemotherapy unit ambient temperature was adjusted to 21°C 
via air-conditioning. Randomization for limb cooling was carried 
out and the non-cooled limb served as internal control prior to 
the first cycle of therapy, and the same limb underwent cooling 
for all subsequent cycles, while the non-cooled limb remained as 
control (Figure 2A).
Limb hypothermia sessions comprised of a pre-cooling period 
(1  h), continued with paclitaxel infusion and a post-cooling 
period (on average 30 min after the end of paclitaxel infusion) 
(Figure  1A). Overall, hypothermia was administered for no 
longer than 4  h. A detailed safety protocol was followed for 
coolant thermoregulation, if the patient found the hypothermia 
intolerable (Tables S1 and S2 in Supplementary Material).
Safety and tolerance of limb hypothermia were measured using 
three validated scales: visual analog pain scale (VAS), subjective 
tolerance scale, and the Shivering Assessment Scale (Figure S1 
and Tables S3 and S4 in Supplementary Material) (13, 14). Skin 
surface temperature was continuously recorded throughout limb 
hypothermia via temperature sensors (accurate to ±0.1°C) placed 
at seven locations on both the legs (Figure 2B) (12). Body core 
temperature was measured over the frontal non-glabrous scalp 
(Figure 1A).
than in the control limbs, but the difference did not attain statistical significance. One 
patient with a history of diabetes mellitus had significant preservation of compound 
muscle action potential in the cooled limb on NCS analysis.
conclusion: This study suggests that continuous limb hypothermia accompanying 
paclitaxel infusion may reduce paclitaxel-induced PN and have therapeutic potential in 
select patients and warrants further investigation. The method is safe and well tolerated.
Keywords: chemotherapy-induced peripheral neuropathy, limb hypothermia, paclitaxel, nerve conduction, 
neuroprotection
FigUre 2 | (a) Continuous-flow limb hypothermia setup by means of a 
thermoregulator device supplying coolant (water) at a set desired temperature 
(22°C) to limb wraps that cool the limb. Continuous skin temperature data 
are acquired via a temperature monitoring system consisting of wireless 
sensors placed at seven different sensor locations on the cooled and control 
legs as indicated in (B), which transmit data wirelessly to a receiver and 
recorded for analysis.
FigUre 1 | (a) Limb hypothermia protocol for one chemotherapy cycle. 
Premedication drugs: dexamethasone, diphenhydramine, and ranitidine.  
(B) Study schema.
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assessment of neuropathy
Assessment for neuropathy was performed using nerve conduc-
tion studies (NCSs) and clinical examination. NCSs are the most 
sensitive and specific detection method for neuropathies and 
superior to clinical examination or scores (15). Primary end-
point was differences in NCSs carried out at baseline (NCSbaseline), 
1 month into treatment (NCSmid), the end of treatment (NCSend), 
and 3 months post-treatment (NCS3m) (Figure 1B). Sensory nerve 
action potential (SNAP) amplitudes and conduction velocities 
were measured in the bilateral sural, superficial peroneal, saphen-
ous, and medial and lateral plantar nerves (16). Compound motor 
action potential (cMAP) amplitudes and motor nerve conduction 
velocities were evaluated in the bilateral common peroneal and 
tibial nerves (17).
At the same time points, clinical evaluation using the validated 
Total Neuropathy Score (TNS) was performed (18).
statistical analysis
Temporal trend of skin temperature variation over the duration 
of hypothermia was summarized as an average of the recorded 
temperatures for all cycles of cooling for all the patients. Similarly, 
tolerability was analyzed as an average of all patients’ tolerance 
scores across all cycles of cooling. Sensory and motor nerve 
parameters of amplitude and velocity at every NCS visit were 
analyzed as relative percentage changes with respect to the first 
NCS visit (NCSbase) and averaged across patients.
We assessed the effect of varying amounts of cooling on nerve 
conduction parameters through correlation analysis (Pearson). 
Limb cooling was quantified by calculating each patient’s average 
reduction in baseline skin temperature over 12 cooling cycles. 
Limb cooling was correlated with mean SNAP amplitude/veloc-
ity percentage changes at the sural, superficial peroneal, and 
saphenous nerves. Similarly, limb cooling was correlated with 
mean cMAP amplitude/velocity percentage changes from all 
peroneal nerve stimulation points (ankle, below fibula head, and 
above fibula head) at the recording site of the extensor digitorum 
brevis (EDB) and from the tibial nerve ankle stimulation point 
on the abductor hallucis. This was done for values obtained at 
NCSend and NCS3m. A negative correlation shows that more cool-
ing results in better preservation of nerve conduction parameters. 
Comparison of three different degrees of cooling achieved and 
the relation to the degree of preservation on nerve conduction 
parameters were also assessed.
Continuous variables are shown as mean ± SD. A parametric 
paired t-test was used to compare the changes in temperature 
and NCS values of the cooled and control limbs in each patient. 
A two-tailed p-value <0.05 was considered statistically sig-
nificant. The Pearson’s correlation coefficient was calculated 
to determine the correlation between amount of limb cooling 
and NCS preservation. All statistical analyses were performed 
in Microsoft Excel (V.12.0 for Windows, Microsoft Corp., 
Washington, DC, USA).
resUlTs
Twenty female breast cancer patients were enrolled in the study 
(Table 1). Of these 20 patients, 17 (85%) completed 12 cycles of 
TaBle 1 | Baseline patient characteristics.
Variables N (%) (total 
N = 20)
Mean (range)
Age (years) 53 (32–67)
Weight (kg) 60 (38–81)
Height (cm) 154 (135–167)
BSA (m2) baseline 1.6 (1.2–1.9)
Cumulative dose of paclitaxel (mg/m2) 868.0 (160.0–960.0)
Cancer stage –
Stage 1 3 (15)
Stage 2 11 (55)
Stage 3 5 (25)
Stage 4 1 (5)
Type of surgery –
Breast conservation 5 (25)
Mastectomy 15 (75)
Lymph node assessment –
Sentinel lymph node biopsy 9 (45)
Axillary clearance 8 (40)
Both 3 (15)
ER-positive 18 (90) –
Her-2-positive 3 (15) –
Concurrent herceptin 3 (15) –
TNS baseline –
0 15 (75)
1 4 (20)
2 1 (5)
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continuous-flow limb hypothermia and one patient developed 
an infected seroma after her ninth cycle and deemed not fit for 
further paclitaxel by the treating oncologist. The abovemen-
tioned 18 patients completed all TNS and nerve conduction 
assessments before and after chemotherapy and were included 
in the analysis of nerve conduction changes and assessment 
of clinical neuropathy. The remaining two patients who were 
enrolled in the study did not complete all assessments and hence 
were not included for analysis of nerve conduction changes 
and assessment of clinical neuropathy [one patient completed 
two cycles before discontinuing due to development of grade 
3 PN. Another withdrew from the study after three cycles due 
to ineligible inclusion criteria (not adjuvant therapy, Stage IV 
disease)]. However, all the 20 enrolled patients were included 
for safety and tolerability analysis.
safety and Tolerability
Continuous-flow limb hypothermia was well tolerated by all 
patients. Premature termination of cooling was never necessary 
and only one patient (for 2 out of a total 218 cycles) required one 
intra-cycle thermoregulator temperature increase of 1°C toward 
the end of a hypothermia session (Figure S2 in Supplementary 
Material). Overall, minimal discomfort was reported at the end 
of each limb hypothermia session. No serious or lasting adverse 
events as a result of hypothermia were encountered. Only tempo-
rary erythema lasting a few minutes was observed upon removal 
of the cooling wrap. All recorded adverse events were due to 
chemotherapy (Table S5 in Supplementary Material). Patients’ 
core body temperature showed negligible changes (0.03 ± 0.18°C) 
across chemotherapy cycles.
skin Temperature changes with limb 
hypothermia
Skin temperature changes at all the seven sensor locations on the 
cooled and control limbs were calculated and averaged across all 
patients over all 218 cycles. Following the onset of hypothermia, 
skin temperatures of the cooled leg showed significantly lower 
temperatures than the control leg (p = 0.0003) (Figures 3A–G). 
A mean temperature drop of 1.5 ±  0.7°C was achieved across 
all sensor points on the cooled limb and averaged across all the 
patients. The largest temperature drops in the cooled limb was 
achieved in the shin (2.2 ±  1.1°C) (Figure  3B) and foot arch 
(2.2 ± 1.3°C) (Figure 3G).
clinical neuropathy
Assessment of neuropathy using clinical and nerve conduc-
tion parameters of 18 patients was done. The TNS grade of PN 
reported during all the four visits were documented (Figure S3 
in Supplementary Material). Baseline TNS ranged between 0 
and 2 for all patients, thereby indicating absence of any baseline 
neuropathy. As per the National Cancer Institute-Common 
Toxicity Criteria grading of neuropathy (19), sensory PN of 
the following grades were experienced by patients at the end of 
chemotherapy: grade 3 PN occurred in two patients (10%), grade 
2 in two patients (10%), grade 1 in 12 patients (60%), and grade 
0 in four patients (20%). One patient developed grade 3 PN after 
two cycles and dropped out of the study. She was included for 
safety analysis but not efficacy analysis. The other patient with 
grade 3 PN completed all 12 cycles. Both patients with grade 2 
PN completed 12 cycles of limb hypothermia.
nerve conduction changes
The SNAP amplitudes showed decreasing trend over time, 
in both cooled and control limbs (Figures  4A–C; Table S6 in 
Supplementary Material). While the sural nerve showed more 
preservation of SNAP amplitude in the cooled than in the control 
limb at NCS3m, the difference was not significant [−19.9 ± 23.7% 
(cooled) vs. −25.8  ±  21.8% (control), p  =  0.16]. Sensory 
velocities between the limbs showed no significant difference 
(0.09 <  p <  0.89) (Figures  4D–F; Table S6 in Supplementary 
Material).
The cMAP amplitudes of all recorded motor nerves were more 
preserved in the cooled limb than the control limb (Figures 4G–I; 
Table S7 in Supplementary Material) at NCS3m, without reach-
ing significance. At NCS3m, the EDB cMAP amplitudes of the 
cooled limb showed more preservation [stimulation below 
fibula head: −2.1 ± 25.3% (cooled) vs. −18.3 ± 30.0% (control), 
p = 0.07; stimulation above fibula head: −4.3 ± 23.9% (cooled) 
vs. −18.7 ± 32.0%, p = 0.10] (Figure 4G). Motor velocities did 
not show significant change between limbs (Figures 4J–L; Table 
S7 in Supplementary Material).
We identified one subject who experienced significant 
preservation of cMAP amplitudes (EDB) in the cooled leg, 
FigUre 3 | Trend of skin temperature of the cooled (blue) vs. control (red) leg over the duration of limb hypothermia in breast cancer patients. Skin 
temperature was acquired continuously at various sensor locations: (a) below knee, (B) at the shin, (c) calf, (D) dorsum of the foot, (e) toe (hallux), (F) first 
metatarsal head, and (g) foot arch (foot plantar). Skin temperatures of the cooled leg showed significantly lower temperatures than the control leg at each time point 
(p < 0.05). Limb hypothermia was administered at a coolant temperature of 22°C throughout the duration of chemotherapy.
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compared to the control leg (Figure 5). This was a 64-year-old 
female patient with Stage II hormone receptor-positive and 
Her2-positive breast cancer. She had a history of diabetes with 
an Hba1c of 7.3% at the time of her screening visit. She had no 
pre-existing neuropathy from her diabetes with a baseline TNS 
score of 1.
While her cMAP (EDB) amplitudes in the cooled and con-
trol legs were below baseline for NCSmid, NCSend, and NCS3m, 
FigUre 4 | continued
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separation between cMAP in the cooled and control legs was 
shown at NCSend where cMAP amplitude (EDB, ankle stimula-
tion) was 41.8% higher in the cooled leg than the control leg. 
At NCS3m, cMAP amplitude (EDB, ankle stimulation) was 53.2% 
higher in the cooled leg.
effect of the amount of limb cooling on 
ncs
The greatest negative correlation was between cooling and 
cMAP recordings over the EDB with distal stimulation at 
NCS3m (r  =  −0.55). SNAP amplitudes and limb cooling 
FigUre 4 | Percentage change of sensory nerve action potential (snaP) amplitudes (a–c) and velocities (D–F), and compound motor action 
potential (cMaP) amplitudes (g–i) and velocities (J–l) over four nerve conduction study visits from baseline.
7
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did not show a large correlation at NCSend (r  =  −0.17) or 
NCS3m (r = −0.13).
To ascertain whether different degrees of cooling achieved 
different preservation of cMAP amplitude, three different 
degrees of cooling were plotted against the achieved preservation 
in cMAP. All groups showed highly significant differences: high 
(Δt > −2.2°C) vs. moderate cooling (Δt 2.2–1.5°C) (p = 0.002); 
moderate vs. low cooling (Δt < −1.5°C) (p = 0.0006) (Figure 6).
DiscUssiOn
Our study shows that continuous-flow limb hypothermia using 
coolant temperatures of 22°C lasting the duration of paclitaxel 
chemotherapy is well tolerated and safe. Limb hypothermia with 
higher degrees of cooling significantly preserves selected nerve 
motor amplitudes at 3 months after start of chemotherapy.
safety and Tolerability of continuous-Flow 
limb hypothermia
Our results show good tolerability (Figure S2 in Supplementary 
Material) and, importantly, no early termination of cooling.
Various limb cooling modalities are used for different thera-
peutic interventions, most of which involve the direct application 
of ice or frozen gloves and cause steep cooling gradients with 
varied and often poor tolerability (20). Large cooling gradients 
permit only intermittent coolant application and are limited 
by significant intolerance and sometimes frostbite (21, 22). 
Advantages of continuous-flow limb cooling with thermoregu-
lation features are controlled and more tolerable temperature 
reduction for the duration of chemotherapy infusion with better 
outcomes (21). Concern could be raised regarding cold-induced 
nerve damage, which is known to occur, depending on length 
and degree of cooling. The work by Jia et  al. has examined in 
detail the required circumstances for cold-induced ischemia to 
occur in animal experiments (23). It is concluded that cooling the 
sciatic nerve for 3 h at 2°C does not result in vascular occlusions 
or morphological change in the nerves suggestive of ischemia 
from vasoconstriction. Looking at the difference in temperatures 
it is unlikely that 22°C cooling will be able to result in additional 
counteractive ischemia.
skin Temperature and hypothermia
Limb hypothermia caused significant decrease in skin tempera-
ture in the cooled limb across all sensor locations (Figure 3), while 
body core temperature was unaffected. The majority of cooling 
occurred in the first 60 min, consistent with other studies (24). 
Taking into consideration the objective of inducing maximal 
vasoconstriction before the initiation of chemotherapy, a period 
of pre-cooling, may be crucial (25). Hypothermia-induced 
vasoconstriction should be maintained throughout the duration 
of chemotherapy (12). All of these conditions were met by our 
study.
In studies of scalp cooling to prevent CIA, subcutaneous scalp 
temperature (depth 1–2 mm) had to be less than 22°C to prevent 
doxorubicin-induced alopecia (26). To achieve a subcutaneous 
temperature of 22°C, a surface scalp temperature of 19°C was 
necessary (27). Our study only achieved a mean skin surface 
temperature of 26.0 ± 0.8°C on the cooled limb. Although the tar-
geted tissues are different, the temperature achieved in our study 
seems modest to achieve neuroprotection. We utilized a coolant 
temperature of 22°C based on this representing maximum toler-
ability for 3 h of continuous cooling (12). Future studies will need 
to explore techniques such as cryocompression to achieve more 
cooling while ensuring tolerability (28).
Although thermoregulator temperature was constant (22°C), 
different patients achieved different amounts of limb cooling due 
to varying body surface area and factors beyond experimental 
control, such as intermittent toilet breaks. On average, each 
patient took one toilet break per chemotherapy cycle typically 
lasting 5–7 min, during which limb wraps were removed. Toilet 
FigUre 5 | comparison of changes in compound motor action 
potential (cMaP) amplitudes in the cooled and non-cooled limb of a 
subject with well-preserved cMaP amplitudes in the extensor 
digitorum brevis (eDB) muscle on the common peroneal nerve. Over 
the time, the cooled leg showed consistently more preserved compound 
motor action potential amplitudes than the control leg at all the three 
stimulation points [(a) ankle, (B) below fibula head, and (c) above fibula 
head] on the EDB muscle.
FigUre 6 | relation of changes of skin temperature at the calf and 
compound motor action potential (cMaP) amplitude percentage 
changes of extensor digitorum brevis (distal stimulation) cMaP at 
ncs3m, with data grouped into “high” cooling, “moderate” cooling, 
and “low” cooling. Statistical significance (*p < 0.05).
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breaks for trial subjects were similar in nature to chemotherapy 
patients not undergoing limb hypothermia with respect to 
frequency and duration and were not likely increased due to 
hypothermia. These breaks were mostly immediately before or 
after the end of paclitaxel infusion itself (Figure 1A).
changes in sensory and Motor nerve 
conduction Parameters
Both SNAP and cMAP amplitudes represent the number of 
functioning axons within each nerve. Lower amplitude reflects 
chemotherapeutic axonal damage, whereas reduction in velocity 
signifies nerve myelin sheath dysfunction (29, 30). Our results 
concur with the literature in showing paclitaxel-induced PN is 
predominantly axonal, length dependent, and sensory predomi-
nant (1).
Our study is the first to systematically record motor function 
over the course of chemotherapy using sensitive parameters 
(cMAP) and reveals frequent motor involvement. Clinical 
examination used in clinical scoring (TNS) was not able to 
detect motor involvement. Likely, this is because of poor 
sensitivity which explains the low rates of involvement in the 
literature (31).
It is important to consider why motor nerve parameters (cMAP) 
showed more effect to hypothermia than sensory parameters. 
cMAP amplitude, in contrast to sensory parameters, is dependent 
not only on nerve axonal function but additionally on muscle 
fiber function. Considering that paclitaxel motor neuropathy 
is rare (32) and myopathy is poorly identified with the TNS 
examination utilized, we suggest much of cMAP change could 
be from paclitaxel-induced myopathy. The infrequent reporting 
of myopathy in the literature is likely due to poor methods of 
detection (33).
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Our hypothesis for the prevention of CIPN suggests that 
hypothermia reduces paclitaxel delivery to the nerve. Since hypo-
thermia induces reduced blood flow to all exposed tissues, both 
motor axonal and myopathic components could underlie cMAP 
preservation (34). We postulate that prevention of myopathy may 
play a bigger role since hypothermia will affect muscle more than 
nerve based on the greater abundance of muscle tissue and the 
absence of a nerve–blood barrier.
Overall, our primary endpoint of differences in nerve conduc-
tion parameters between cooled and non-cooled limbs did not 
reach significance (Figure 4). Considering the modest degree of 
limb cooling achieved, we were particularly interested in assess-
ing the effect of different degrees of cooling achieved. A good 
correlation (r = −0.55; p < 0.001) was found between the amount 
of cooling and the mean cMAP amplitude percentage changes at 
3 months after the end of chemotherapy. This suggests that the 
degree of limb hypothermia achieved is crucial to the amount 
of cMAP preservation. Cluster analysis between high, moderate, 
and low amounts of cooling further showed significantly differ-
ent amounts of cMAP amplitude preservation (Figure 6). This 
corresponds to observations suggesting a minimal threshold of 
temperature reduction for the prevention of alopecia (26). One 
patient benefited significantly from limb hypothermia, reflected 
through her NCS analysis. Several factors may have influenced 
this result including her history of diabetes, genetic predisposi-
tion, or concomitant medications. While sub-group analysis for 
these characteristics were not possible due to limited numbers, 
analysis of a larger cohort of patients undergoing limb hypo-
thermia may identify predictive biomarkers for those who may 
benefit from such therapy.
Our study is adversely affected by the relatively small sample 
size and clinical methods that are not sensitive for assessment of 
mild or moderate degrees of motor dysfunction. Furthermore, 
only relatively modest degrees of limb cooling were achieved. 
While the lack of formal quality-of-life analysis in our study is a 
limitation, it was partially replaced by our safety scoring systems 
which did not reflect any concern. Future studies will also need 
to include more specific tests to determine the thresholds for 
mechanical and temperature sensitivity, or muscle strength, and 
to reveal alterations in sensory and motor functions related to 
neuropathy and myopathy (including plasma markers), as well as 
quality-of-life measures. A larger study using cryocompression 
of all four limbs is currently underway to prove efficacy. Studies 
to detect predictive biomarkers for paclitaxel-induced PN and to 
potentially identify patients from these protective therapies are 
also being conducted (35). Animal studies are also being per-
formed to establish proof of reduced delivery of chemotherapy to 
neurons through limb hypothermia.
In summary, our results suggest that limb hypothermia, given 
for the duration of paclitaxel chemotherapy, preserves certain 
nerve conduction parameters. Preservation is directly related to 
the degree of limb cooling.
cOnclUsiOn
Our findings open up a new opportunity for more research to 
be conducted toward the goal of achieving neuroprotection and 
preventing CIPN via a simple, non-invasive, and non-pharma-
cological method. As neuropathy is an important factor leading 
to chemotherapy dose reduction and treatment discontinua-
tion, this research may contribute to alleviating dose limitation 
and increase the likelihood of success of chemotherapy. While 
our results revealed some interesting findings, it must only be 
regarded as a pilot study and larger studies achieving well toler-
ated and greater limb cooling are now needed.
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